All podcasts


Time-limited venetoclax and ibrutinib for patients with R/R CLL and undetectable MRD

Prof. Carsten Niemann, Department of Clinical Medicine, University of Copenhagen, Denmark

Talha Munir about ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for CLL patients

Dr. Talha Munir, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom

Prof. Susan O’Brien about the value of acalabrutinib in CLL

Prof. Susan O’Brien, University of California Irvine, United States

Dr. Davide Rossi: “How to optimize the first-line treatment for patients with CLL?”

Dr. Davide Rossi, Deputy Head of the Division of Hematology of the Oncology Institute of Southern Switzerland IOSI and Head of the Laboratory of Experimental Hematology at the Institute of Oncology Research IOR in Bellinzona, Switzerland

Dr. Ann Van de Velde about Sickle Cell Disease; more than sickled red blood cells

Dr. Ann Van de Velde, Head of the Haematology Clinic, University Hospital of Antwerp

The burden of CMV infection and real-life data of CMV prophylaxis

Dr. Anke Verlinden, Hematologist at University Hospital Antwerp